Fluoroquinolones

ApprovedSmall molecule

Johnson & Johnson

Fluoroquinolones is one of 50 small molecule programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

KeratitisActive, not recruiting

PneumoniaApproved

Active, not recruiting

KeratitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Fluoroquinolones

Johnson & Johnson

Approved

1 2

Acanya

Pfizer

Preclinical

1 3

Prevacid

Takeda

Preclinical

1 4

Innohep

Alnylam Pharmaceuticals

Preclinical

1 5

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 6

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Zantac 150

CChattem

Preclinical

2 8

Pepcid

KKenvue Brands

Preclinical

1 9

Mycifradin

PPharmacia and Upjohn

Preclinical

1 10

Ofev

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Randomized1 trial

Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

Completed·NNorthwell Health·Phase 3·NCT02579161·98 enrolled

Keratitis1 trial

Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis

Completed·UUniversity Hospital, Geneva·Phase 3·NCT02717871·35 enrolled

Fluoroquinolone1 trial

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03479736·117,911 enrolled

Pneumonia1 trial

Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia

Unknown status·QQingfeng Pharmaceutical Group·Phase 4·NCT02913118·462 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fluoroquinolones. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluoroquinolones compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluoroquinolones. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Fluoroquinolones

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Randomized1 trial

Keratitis1 trial

Fluoroquinolone1 trial

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News